Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Frigault

Showing results (11-20 of 117) with videos related to

Pageof 12
Sort By:
Current Hematologic Malignancy Reports|February 25, 2017
CARs in the Lead Against Multiple MyelomaMaria Ormhøj, Felipe Bedoya, Matthew J Frigault, et al.
Hematological Oncology|December 17, 2024
Post-CAR T-Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B-Cell LymphomaHazim S Ababneh, Matthew J Frigault, Andrea K Ng, et al.
Hematological Oncology|December 16, 2023
Radiation therapy as bridging and salvage strategy among patients with secondary central nervous system lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapyHazim S Ababneh, Matthew J Frigault, Andrea K Ng, et al.
Journal for Immunotherapy of Cancer|December 22, 2022
Dose-response correlation for CAR-T cells: a systematic review of clinical studiesAnand Rotte, Matthew J Frigault, Ayub Ansari, et al.
The New England Journal of Medicine|October 13, 2021
Case 31-2021: A 21-Year-Old Man with Sore Throat, Epistaxis, and Oropharyngeal PetechiaeHanno Hock, Hillary R Kelly, Eric A Meyerowitz, et al.
Journal of the American College of Cardiology|May 16, 2020
Reply: Cardiac Events Associated With Chimeric Antigen Receptor T Cells (CAR-T): A VigiBase PerspectiveRaza M Alvi, Michael G Fradley, Matthew J Frigault, et al.
American Journal of Hematology|June 11, 2024
Radiotherapy as a bridging strategy for patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapyHazim S Ababneh, Andrea K Ng, Matthew J Frigault, et al.
Transplantation and Cellular Therapy|February 27, 2024
Clinical Outcomes and Toxicity in Older Adults Receiving Chimeric Antigen Receptor T Cell TherapyP Connor Johnson, Isabel Neckermann, Hossein Sadrzadeh, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 24, 2026
Outcomes of combined bispecific antibody and radiation therapy in relapsed/refractory hematologic malignanciesHazim S Ababneh, Andrew J Yee, Noopur S Raje, et al.
The Journal of Infectious Diseases|December 20, 2021
False-Positive Human Immunodeficiency Virus Test Results in Patients Receiving Lentivirus-Based Chimeric Antigen Receptor T-Cell Therapy: Case Report, Review of the Literature, and Proposed RecommendationsJulian A Villalba, Marcela V Maus, Matthew J Frigault, et al.
Pageof 12

Showing results (11-20 of 117) with videos related to

Sort By:
Pageof 12
Current Hematologic Malignancy Reports|February 25, 2017
CARs in the Lead Against Multiple MyelomaMaria Ormhøj, Felipe Bedoya, Matthew J Frigault, et al.
Hematological Oncology|December 17, 2024
Post-CAR T-Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B-Cell LymphomaHazim S Ababneh, Matthew J Frigault, Andrea K Ng, et al.
Hematological Oncology|December 16, 2023
Radiation therapy as bridging and salvage strategy among patients with secondary central nervous system lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapyHazim S Ababneh, Matthew J Frigault, Andrea K Ng, et al.
Journal for Immunotherapy of Cancer|December 22, 2022
Dose-response correlation for CAR-T cells: a systematic review of clinical studiesAnand Rotte, Matthew J Frigault, Ayub Ansari, et al.
The New England Journal of Medicine|October 13, 2021
Case 31-2021: A 21-Year-Old Man with Sore Throat, Epistaxis, and Oropharyngeal PetechiaeHanno Hock, Hillary R Kelly, Eric A Meyerowitz, et al.
Journal of the American College of Cardiology|May 16, 2020
Reply: Cardiac Events Associated With Chimeric Antigen Receptor T Cells (CAR-T): A VigiBase PerspectiveRaza M Alvi, Michael G Fradley, Matthew J Frigault, et al.
American Journal of Hematology|June 11, 2024
Radiotherapy as a bridging strategy for patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapyHazim S Ababneh, Andrea K Ng, Matthew J Frigault, et al.
Transplantation and Cellular Therapy|February 27, 2024
Clinical Outcomes and Toxicity in Older Adults Receiving Chimeric Antigen Receptor T Cell TherapyP Connor Johnson, Isabel Neckermann, Hossein Sadrzadeh, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 24, 2026
Outcomes of combined bispecific antibody and radiation therapy in relapsed/refractory hematologic malignanciesHazim S Ababneh, Andrew J Yee, Noopur S Raje, et al.
The Journal of Infectious Diseases|December 20, 2021
False-Positive Human Immunodeficiency Virus Test Results in Patients Receiving Lentivirus-Based Chimeric Antigen Receptor T-Cell Therapy: Case Report, Review of the Literature, and Proposed RecommendationsJulian A Villalba, Marcela V Maus, Matthew J Frigault, et al.
Pageof 12